Each section starts with a plain summary. Where there is more, a “More detail” button under the summary opens the technical version and its sources, just for that section. Specialist terms have a dotted underline the first time they appear in a section: tap one for a short definition.
How the brain is organised
Prion disease destroys nerve cells, and what a person loses depends on which parts of the brain are affected. This short map covers the regions named later on the page.
- Cerebral cortex. The wrinkled outer layer. It handles thinking, memory, planning, speech, vision and voluntary movement.
- Cerebellum. At the back of the head. It keeps you balanced and movements smooth, and helps coordinate speech.
- Thalamus. Deep in the centre. It acts as a relay station, passing signals from the senses to the cortex and filtering what reaches awareness. It also helps switch sleep on and off. Fatal familial insomnia damages it first.
- Hypothalamus. Just below the thalamus. It controls hormones, body temperature, hunger and the sleep-wake cycle.
- Brainstem. Joins the brain to the spinal cord and runs automatic functions such as breathing and heart rate.
Which regions are hit first differs between people and between forms of prion disease, which is why symptoms vary. One proposed model is that, in FFI, damage to the thalamus cuts its links with other parts of the brain's emotion and memory circuits (the limbic system). That would release the hypothalamus and brainstem from the brakes the cortex normally applies, which could explain why the person cannot sleep and the body stays overactive, with fast heart rate, high blood pressure and sweating.
Sources: Visible Body: The human brain (general anatomy); NHS: CJD; Provini et al. below.
More detail thalamic nuclei and the limbic disconnection model
The thalamus contains first-order relays that carry sensory signals to the cortex (the lateral geniculate nucleus for vision, for example) and higher-order relays that route information between cortical areas. It also gates what is forwarded, and its inhibitory neurons help generate the rhythms that begin and sustain non-REM sleep. Its role in consciousness is supported but not conclusively established.
In FFI, degeneration centres on the “visceral” thalamus, notably the mediodorsal and anteroventral nuclei. The proposed mechanism for agrypnia excitata is an intralimbic disconnection that releases the hypothalamus and the brainstem reticular formation from cortico-limbic inhibitory control. The same authors describe sleep-wake control as an integrated network running from the medulla to the limbic cortex. This is a review-level model rather than a settled account, and it is also proposed for two non-prion conditions that cause agrypnia excitata.
Moustafa AA et al. The thalamus as a relay station and gatekeeper. Rev Neurosci 2017;28(2):203–218. Provini F. Agrypnia excitata. Curr Neurol Neurosci Rep 2013;13(4):341. Provini F et al. Fatal insomnia and agrypnia excitata: sleep and the limbic system. Rev Neurol (Paris) 2008;164(8–9):692–700.
Where these regions sit
A side view of the head with the brain cut down the middle, so the deep structures show; front on the right. Positions are approximate, not an anatomical atlas, and the hypothalamus is marked as a region.
Brain and skull drawings: Servier Medical Art by Servier, licensed under CC BY 4.0. Adapted: the two drawings were combined and labelled.
What prion disease is
Prion diseases are rare, fatal brain diseases. They all have the same cause. Everyone's nerve cells carry a normal protein called the prion protein. In these diseases some of it folds into the wrong shape, and each misshapen copy pushes normal copies into the same wrong shape. The misfolded protein builds up and kills nerve cells, and over time the brain tissue can take on a sponge-like appearance under the microscope.
The damage usually spreads quickly. Depending on which parts of the brain are hit first, people lose memory and reasoning, balance and coordination, speech, or, in fatal familial insomnia, the ability to sleep. Most people with CJD die within a year of their first symptoms. Prions are unusually tough: the heat and radiation that kill bacteria and viruses do not destroy them, and antibiotics and antiviral drugs have no effect.
The disease arises in three ways:
- By chance (sporadic). The protein misfolds for no known reason. This is the commonest form: roughly 85 to 90 cases in every 100. In the UK it affects one to two people in every million each year, usually aged 45 to 75 (the average age at onset is 67), though it has been recorded from childhood to old age. It usually begins as a rapidly worsening dementia, often with jerking movements and unsteadiness. The median survival from first symptoms is about five months, but it ranges from weeks to years.
- Inherited (genetic). A change in the prion protein gene, passed down in families, makes misfolding far more likely. About one case in ten worldwide is genetic. More than 50 harmful changes in the gene are known, and some cause a slowly progressing illness. Genetic CJD, Gerstmann-Sträussler-Scheinker disease (GSS) and fatal familial insomnia (section 4) belong here.
- Acquired (by infection). Very rare. In the past it came from medical treatment, such as growth hormone taken from human glands before 1985, or from eating beef infected with BSE (“mad cow disease”), which caused variant CJD. The most recent UK death from variant CJD was in 2016, and the total of recorded UK cases has stayed at 178 since then (NCJDRSU annual report 2021). Contaminated surgical instruments and kuru, a disease once seen in Papua New Guinea, are covered under More detail.
CJD is not spread by everyday contact such as touching or coughing, according to UK public-health guidance.
CJD, GSS and fatal familial insomnia are names for different ways the same underlying disease shows itself. This guide groups them by that shared cause because it matters for treatment: one protein is the target for every form.
Sources for the figures in the list: Williams et al., BMC Palliat Care 2026 (full text read; sporadic share, UK incidence, age and survival, inherited share, number of PRNP changes); Hermann et al., Lancet Neurol 2021 (full text read).
Sources: NHS: Creutzfeldt-Jakob disease; NCJDRSU annual report, 1990–2023; Gao et al. 2024; Public Health England leaflet on CJD, 2018 (everyday contact).
More detail the normal and misfolded protein, and why the field groups by cause
The normal prion protein (PrPC) is encoded by the PRNP gene. In disease it converts to a misfolded, self-propagating form (PrPSc) that templates further conversion. Because one gene gives rise to one protein that is the sole causal agent, researchers increasingly organise the field by molecular cause rather than by syndrome name.
Sporadic CJD subtypes. Sporadic CJD is not one uniform illness. It is divided into molecular subtypes by two features of the brain’s misfolded protein: the codon 129 genotype (MM, MV or VV) and the protein’s type (1 or 2), which gives labels such as MM1 and VV2. The subtypes differ in symptoms, test results and course. MM1/MV1 and VV2 are the commonest; VV1 (about 1% of sporadic cases) and MM2 (about 5%) are rarer, and some tests work less well in them (see Diagnosis).
Acquired forms. A 2016 review counted more than 492 cases of iatrogenic CJD worldwide (the authors’ figure from a personal communication in 2015). Most came from two sources: human growth hormone prepared from human pituitary glands, and grafts of dura mater, the membrane around the brain. For dura mater grafts, over 60% of cases were in Japan, with a mean incubation period of about 12 years (range 1.2–30). For growth hormone the mean was about 17 years (range 5–42); in France 119 of 1,170 patients treated between December 1983 and July 1985 developed the disease, and in the US government programme no case was found among recipients who began treatment after 1977, when a purification step was added. Other sources were corneal transplants, deep-brain recording electrodes and neurosurgical instruments (fewer than nine probable instrument-related cases have been reported). Variant CJD has a younger onset than sporadic CJD (median age about 26 to 29 years) and a median duration of 14 months, according to the 2026 systematic review; the 2016 review records three clinical cases of vCJD, and two infections without illness, passed on through blood transfusion. Kuru affected the Fore people of Papua New Guinea from about 1910 and spread through the ritual eating of dead relatives; cases fell sharply after the practice was abandoned in the early 1960s, but have occurred up to 50 years after exposure.
Other rare forms. GSS, a slowly progressive inherited disorder of balance and coordination, is estimated at 1 to 10 cases per 100 million people per year. Variably protease-sensitive prionopathy (VPSPr) is estimated at 2 to 3 per 100 million per year; its median onset is about 70 years and its median duration about two years, it often begins with psychosis, mood change or speech difficulty, and its pattern of codon 129 genotypes differs from that of sporadic CJD. Sporadic fatal insomnia (see the glossary) is a sporadic prion disease with FFI-like thalamic damage but no PRNP change.
Bonda DJ et al. Human prion diseases: surgical lessons learned from iatrogenic prion transmission. Neurosurg Focus 2016 (full text read; includes the kuru, GSS and VPSPr figures). Williams et al. Palliative care symptoms of people living with rapidly progressive prion diseases: a systematic review. BMC Palliat Care 2026 (full text read; vCJD age and duration). Hermann P et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol 2021 (full text read). Ng D et al. Characterisation of RT-QuIC negative cases from the UK National CJD Research and Surveillance programme. J Neurol 2024 (full text read; subtype frequencies).
Vallabh SM et al. Towards a treatment for genetic prion disease. Lancet Neurol 2020. Mead S et al. Genetic causes and modifiers of prion diseases. Lancet Neurol 2026.
The prion protein and the PRNP gene
Everyone carries the prion protein on their nerve cells. Its normal job is still not fully understood. The instructions for making it sit in one gene, PRNP. A small change in that gene can make the protein more likely to misfold, which is why some prion disease runs in families.
Does the normal protein fold properly? Yes. Like any protein, it is made as a chain that curls up into a set shape: a floppy tail, and a compact folded body built mainly from coiled spirals (helices). That shape is stable in healthy cells. In disease the chain takes a different shape, built from flat sheets, and this is the shape that is passed on. Scientists have two main models for how the first misfolded copy arises (see More detail, below). In both it is a rare event, but once it has happened it can recruit other copies. Why inherited gene changes make it more likely is still being worked out, and laboratory studies disagree. The detailed maps of the misfolded form cited here come from mouse and hamster prions.
Mice bred without the protein survive, although they develop a problem with the insulation (myelin) of their peripheral nerves, and some healthy older people naturally have one working copy of the gene instead of two. Together these are reasons to investigate lowering the amount of prion protein as a treatment. They do not show that long-term lowering is safe in people; that is what the early trials are testing.
More detail penetrance figures, protein structure, conversion models and stability studies
PRNP lies on chromosome 20. Pathogenic variants alter the propensity of PrP to convert; the common methionine/valine polymorphism at codon 129 modifies susceptibility and phenotype. Penetrance varies widely between variants, from under 0.1% to around 100% lifetime risk. A 2026 follow-up of US individuals with positive antemortem genetic tests supports high penetrance of D178N: the estimated median age at death was 57 in the abstract and 58 in the results text (the paper gives both), against 52 in retrospective data; the difference was not statistically significant. For E200K, prospective follow-up gave 69% penetrance by age 80 and a median age at death of 75, significantly lower than retrospective estimates. These are cohort estimates from a single US surveillance centre. The D178N figure rests on 31 initially asymptomatic individuals and 6 observed deaths (7 expected from the retrospective data), so it is imprecise.
Lian Y, Kotobelli K et al. Mortality of individuals with PRNP variants associated with prion disease in the United States, 1998–2024. Neurol Genet 2026;12(5):e200423. The journal has published a correction notice (DOI 10.1212/NXG.0000000000200461, dated 20 October 2026). We have read it: it only corrects the corresponding author’s email address and replaces the article with a corrected version, so the figures here are unaffected. Author summary (secondary source): CureFFI.org.
Folding of PrPC. Mature human PrPC has 209 residues, is attached to the cell membrane by a GPI anchor and carries sugar chains (N-glycans). Residues 23–127 are largely unstructured; residues 128–231 form a defined globular domain of three α-helices and a short two-stranded antiparallel β-sheet, with helices 2 and 3 joined by a disulfide bond (Cys179–Cys214). Networks of hydrophobic, aromatic and salt-bridge contacts hold this fold together, and disease-associated point mutations cluster in the folded domain.
How conversion happens. Two models are described and neither is settled. In the template-assistance model PrPC is kinetically trapped: the misfolded form is thermodynamically more stable, but is reached only through a rare spontaneous event or by contact with an existing PrPSc molecule, which then templates refolding. In the nucleation-polymerisation model the two forms interconvert reversibly and PrPC is far more stable; the misfolded form is stable only once a small oligomeric nucleus has formed, nucleation is the slow step, and added seeds can bypass it.
What the misfolded form looks like. Cryo-EM structures of infectious fibrils purified from prion-infected mouse brain (RML and ME7 strains), and a hamster (263K strain) structure described in the same papers, show a parallel, in-register intermolecular β-sheet in which each rung is one PrP molecule; in RML the ordered core spans residues 94–225. These are rodent-adapted strains.
Do inherited mutations destabilise the fold? Sources differ. A 1998 study of recombinant protein found P102L indistinguishable from wild type and E200K only very slightly destabilised, which the authors thought unlikely to explain the disease by itself. The D178N (129M) variant aggregated during preparation, so it could not be measured the same way; the authors suggested this may reflect structural destabilisation, and concluded that destabilisation cannot explain every inherited form. A 2016 study ranked stability as Q212P < D178N < wild type ≈ P105L < V203I and found D178N and Q212P converted more readily. Computer simulations of mouse PrP disagree with each other: one found the β-sheet weaker in D178N, another found no major structural change. A 2013 review concludes that destabilisation holds for a few mutants and that others may act through altered surface properties, binding partners or trafficking. These are laboratory and computational studies, not data from patients.
Giachin G et al. Probing early misfolding events in prion protein mutants by NMR spectroscopy. Molecules 2013;18(8):9451–76 (full text read). Swietnicki W et al. Familial mutations and the thermodynamic stability of the recombinant human prion protein. J Biol Chem 1998 (full text read). Yu Y et al. Distinct effects of mutations on biophysical properties of human prion protein monomers and oligomers. Acta Biochim Biophys Sin 2016 (abstract only; paywalled). Barducci A et al. Metadynamics simulation of prion protein. J Am Chem Soc 2006 (abstract only; paywalled). Gsponer J et al. Flexibility of the murine prion protein and its Asp178Asn mutant. J Mol Graph Model 2001 (abstract only; paywalled). Manka SW et al. 2.7 Å cryo-EM structure of ex vivo RML prion fibrils. Nat Commun 2022 (full text read). Hoyt F et al. Cryo-EM structure of anchorless RML prion. Nat Commun 2022 (full text read in part: the opening sections and structure results). Manka SW et al. A structural basis for prion strain diversity. Nat Chem Biol 2023 (main text read, key sections).
Lowering PrP is a promising strategy supported by animal experiments and by genetic observations in humans: truncating variants that inactivate one copy of PRNP occur in healthy older individuals. PrP knockout mice are viable, but chronic demyelinating peripheral neuropathy has been documented in knockout strains. Neither observation establishes the long-term safety of therapeutic PrP lowering in humans.
Bremer J et al. Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci 2010 (mouse study). Minikel EV et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med 2016. Mead S et al. Genetic causes and modifiers of prion diseases. Lancet Neurol 2026.
One inherited form: fatal familial insomnia
FFI is an inherited form of prion disease, caused by one specific change in the prion protein gene. A parent with the change has a 50% chance of passing it to each child, and almost everyone who inherits it eventually becomes ill, though it is not certain in every carrier. It was first described in 1986 in a large family in the Veneto region of northern Italy whose history of the illness goes back seven generations.
What sets FFI apart is where the damage starts. It first attacks the thalamus, a relay centre deep in the brain that helps switch sleep on and off and controls automatic body functions. The first sign is usually a growing inability to sleep. Deep sleep disappears, and people may drift into a dream-like state while apparently awake, sometimes acting out their dreams.
As the illness advances, heart rate, blood pressure, sweating and body temperature become unstable, and problems follow with memory, movement, balance and speech. Symptoms usually begin in the late 40s or 50s, though cases have been recorded from age 17 to 76. The course is short, on average about a year, but it varies from a few months to four years. A 2026 expert review gives a typical range of 7 to 17 months in its text, and 7 to 25 months in its summary table. Much of that variation comes from the second, unaffected copy of the gene. Position 129 is a spot in the protein where people naturally carry either of two building blocks, methionine or valine, one on each copy of the gene. People who also have methionine at position 129 on that copy live about 11 months on average; those with valine there live about two years.
Two natural questions, and what is known. Why does someone born with the gene change usually stay well until middle age? Nobody has a settled answer. In a study of 1,094 people with high-risk variants, the age when illness began varied over several decades. Which variant a person carries explained only a minority of that variation (about 15%), and neither sex, a parent’s age at onset nor codon 129 explained more; the authors state that no environmental, demographic or other genetic factors are known to affect age at onset, although some may exist. A 2023 paper puts it directly: it is not known why onset is delayed for decades when the mutation is present from birth. Candidate explanations are at the hypothesis stage. A pilot study of 25 FFI patients (all D178N with methionine at 129 on both copies) found gene variants that were present in later-onset but absent in earlier-onset patients; it was exploratory and its authors say it needs confirming in a larger group. A gene called CYP4X1 has also been linked to age at onset, but that finding comes from a different disease: a genome-wide study of inherited CJD caused by the E200K mutation, replicated in sporadic CJD (Poleggi 2018). It did not include FFI, and a 2026 expert review cites it alongside the FFI pilot when noting that other genetic modifiers of onset are being sought. A 2026 laboratory preprint, not yet peer-reviewed, found in cells and in mice carrying bank vole or mouse prion protein (not yet human protein) that the D178N and E200K mutations first produce a misfolded form that did not seed prion formation; the authors hypothesise that it may protect for a time, and note that the protection must eventually fail. Why does the damage start in the thalamus? The 2019 paper below states that it is unknown why a lower amount of misfolded protein in the thalamus than elsewhere in the brain causes such marked thalamic degeneration in FFI. That study, of one Japanese family and ten cases of sporadic fatal insomnia, found that a mother without thalamic and olivary degeneration and her child with it behaved as different prion types in mouse transmission tests, so prion type may help explain the variation between patients, but not why the thalamus is vulnerable.
Minikel EV et al. Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology 2019 (full text read). Bordonaro M. Hypothesis: functional age and onset of autosomal dominant genetic prion disease. Theory Biosci 2023 (abstract only; paywalled; a hypothesis paper). Thüne K et al. Genetic variants associated with the age of onset identified by whole-exome sequencing in fatal familial insomnia. Cells 2023 (full text read). Poleggi A et al. Age at onset of genetic (E200K) and sporadic Creutzfeldt-Jakob diseases is modulated by the CYP4X1 gene. J Neurol Neurosurg Psychiatry 2018 (abstract only; E200K genetic CJD and sporadic CJD, not FFI). Amano G et al. PRNP mutations initially generate an alternatively misfolded PrP species that dissuades prion replication. bioRxiv 2026 (preprint, not peer-reviewed; full text read). Takeuchi A et al. Two distinct prions in fatal familial insomnia and its sporadic form. Brain Commun 2019 (full text read; the journal’s corrigendum, also read, corrects only the graphical abstract, where “positive” and “negative” had been reversed, and does not affect anything cited here). Mead S et al. Genetic causes and modifiers of prion diseases. Lancet Neurol 2026 (full text read, from a copy supplied by the author; the journal itself is behind a subscription).
More detail the D178N-129M genotype, thalamic pathology and survival by codon 129
FFI results from the D178N mutation in PRNP with methionine at codon 129 on the same allele. Pathology centres on selective degeneration of the mediodorsal and anteroventral thalamic nuclei. The clinical syndrome, agrypnia excitata, combines loss of slow-wave sleep with 24-hour motor and autonomic overactivation and episodes of oneiric stupor. Duration depends on codon 129 genotype: in a pooled series of 131 patients (106 had died; the paper does not state how many the duration is based on), mean duration was 13.2 ± 9.0 months overall, 11.1 ± 5.9 months in 129MM and 26.8 ± 13.6 months in 129MV (p = 0.01). Pooled averages therefore shift with the genotype mix of the population studied; 129MM was 95.5% of Asian and 73.8% of non-Asian patients.
The 2026 review led from the National Prion Clinic gives onset generally between 40 and 60 and a “typical survival time of 7–17 months” in its text, but a typical clinical duration of 7 to 25 months in its summary table (Figure 3). The review does not explain the difference between its two figures, and both are given here. They are consistent with the pooled series above, which the review cites: the narrower range brackets the 129MM mean (11.1 months), and the wider one reaches towards the 129MV mean (26.8 months). Neither review range is a mean, and neither is broken down by codon 129.
Zhang J et al. Clinical profile of FFI, J Neurol Neurosurg Psychiatry. Llorens F et al. FFI: clinical aspects and molecular alterations (2017). Baldelli L, Provini F. FFI and agrypnia excitata (2019). Mead S et al. Genetic causes and modifiers of prion diseases. Lancet Neurol 2026 (full text read; FFI section and Figure 3).
One mutation, two diseases
The same change at position 178 of the PRNP gene leads to different illnesses, depending on which version of position 129 sits on the same copy of the gene.
Methionine at 129 Valine at 129 Disease-causing change at 178 (aspartic acid → asparagine)
Who gets it, and where
In the UK, between one and two people in every million die of sporadic CJD each year. Most are in their 60s and 70s; it is very rare before 40. About one case in ten worldwide is genetic, and genetic forms tend to start earlier; section 3 (under More detail) gives cohort estimates of penetrance, meaning how likely carriers are to become ill, for two common variants.
FFI is far rarer. It has been found mainly in Europe and Asia, with growing numbers reported in China. A 2022 pooled series — 11 new patients plus 120 gathered from a systematic literature search — brought together 131 genetically confirmed patients worldwide. Most European cases appear to trace back to two old family lines, one linking Spain and Tuscany, the other Germany and the Veneto.
More detail the global atlas, the UK genetic CJD count and FFI founder lines
A global atlas counted 27,872 prion disease cases, 24,623 of them sporadic CJD (88.3%); genetic forms were 10.83% of the total, varying widely between countries — below 5% in seven of them, against 69.57% in Israel, 60.30% in Slovakia and 36.31% in Hungary. The paper is inconsistent about its own scope: its abstract says 34 countries, its results section 32 countries with accessible surveillance data between 1993 and 2020. Reported numbers are rising, and most low- and lower-middle-income countries run no surveillance, so the true global burden is underestimated.
The National CJD Research & Surveillance Unit (Edinburgh) identified 203 cases of genetic CJD (excluding GSS) since 1970, 21 of them with D178N, in its report covering 1990–2023. The report says these data are incomplete because formal investigation of genetic cases is undertaken by the National Prion Clinic, so this is not a complete count of inherited prion disease in the UK. It does not separate FFI (129M) from genetic CJD (129V). The Edinburgh unit’s national surveillance funding ended in March 2025; surveillance is now led by each UK nation’s public health system, with UKHSA collating the UK figures (NHS England contract notice, February 2026). No UK-wide report of case numbers later than this one had been found by 19 November 2026. UKHSA does publish a yearly “surveillance update” (latest found: 2024, updated 26 June 2025), but its gov.uk summary describes it as covering enhanced surveillance of possible healthcare-acquired exposures to CJD, not counts of cases; we have not read it in full. Its referral table lists no FFI referrals to the Edinburgh unit for 2022 or 2023; that does not mean no FFI occurred in the UK in those years. Among 131 pooled FFI patients, mean onset was 47.5 ± 12.5 years (range 17–76), with a male-to-female ratio of about 1.3 to 1 (72 men, 57 women, 2 unreported). The illness lasted 13.2 ± 9.0 months (range 2–48; the paper reports 106 deaths among the 131 and does not state how many the duration is based on), and its length differed sharply by codon 129 genotype: 11.1 ± 5.9 months for 129 MM against 26.8 ± 13.6 months for 129 MV. A definite family history was documented in 107 of the 131 (81.7%). Codon 129 MM was more common in Asian than non-Asian patients (95.5% against 73.8%).
On the founder question, a six-SNP haplotype study genotyped 25 Spanish, 9 German and 4 Italian FFI patients and found two distinct haplotypes carrying D178N: one shared by the Spanish patients and a Tuscan family, the other by the German patients and a family from the Veneto. Its authors conclude that this suggests two independent D178N-129M mutational events in Europe, and that earlier hypotheses of repeated independent mutation in each family “must be regarded with caution”. This is an inference from 38 patients rather than a settled result, and it drew a published letter and an author reply in the same year.
Gao LP et al. Updated global epidemiology atlas of human prion diseases. Front Public Health 2024 (full text read). Zhang J et al. Clinical profile of fatal familial insomnia. J Neurol Neurosurg Psychiatry 2022;93(3):291–297 (full text read). Rodríguez-Martínez AB et al. Molecular evidence of founder effects of fatal familial insomnia through SNP haplotypes around the D178N mutation. Neurogenetics 2008;9(2):109–18 (abstract read; full text paywalled) — this, not the letter below, is the source of the founder finding. Lee HS, Goldfarb LG. Global distribution of FFI: founder or recurrent mutations. Neurogenetics 2008;9(4):301–2 — a letter commenting on it, with an author reply at 303–4 (abstract read).
Wales has the highest recorded average sporadic CJD mortality in the UK
Crude average sporadic CJD mortality (deaths per million people per year), 1990–2023. These are historical averages, not current incidence. Differences between the nations are small and may partly reflect chance.
The UK-wide rate for 2023 alone was 2.07 per million (figures for that year may be incomplete). Source: National CJD Research & Surveillance Unit annual report, 1990–2023.
Diagnosis
Prion disease is hard to spot early and is often mistaken for something else at first (see “Mistaken for other dementias”, below). In fatal familial insomnia (FFI), for example, poor sleep, low mood, anxiety and forgetfulness are common in middle age and have many ordinary causes. In inherited forms a known family history is often the strongest clue: a definite one was documented in 107 of 131 pooled FFI patients (82%).
Sporadic CJD, the commonest form
A certain diagnosis needs examination of brain tissue, which usually means after death; a brain biopsy in life is rarely done, because of infection-control concerns and because it can miss affected areas. In life, doctors combine the clinical picture with several tests, and the diagnosis is “probable” rather than certain:
- MRI brain scan. A special setting (diffusion-weighted imaging) shows typical bright areas in the brain’s outer layer (“cortical ribboning”) and in deep structures such as the caudate nucleus. In a 2020 study of 770 confirmed cases it identified 92% of them and was correctly negative in 97% of people without CJD; other studies report lower or similar figures.
- Spinal fluid test (RT-QuIC). This detects the misfolded protein itself. It rarely gives a false positive (specificity 99% to 100% in prospective studies), and the newer version picks up 92% to 97% of cases. It misses about one in ten: in the UK national surveillance cohort, 27 of 250 confirmed cases (10.8%) tested negative, and they were younger, lived longer and were more often of two rarer subtypes (VV1 and MM2).
- Other spinal fluid markers (14-3-3 and tau proteins). These rise when nerve cells are damaged quickly, so they support the diagnosis but are not specific: stroke, seizures and inflammation of the brain can also raise them.
- EEG (brain-wave recording). A typical repeating pattern is seen in some people, but it often appears late, and in recent comparisons it was found in fewer than half of cases (39% to 45%).
- Genetic blood test. A 2021 review advises considering PRNP sequencing in every suspected case, even with no family history, to rule out an inherited form and to record the codon 129 genotype.
Routine blood, spinal fluid and imaging tests are also done to rule out treatable look-alikes, such as inflammation of the brain. This matters because even a very small false-positive rate leads to some wrong diagnoses, and the worry is that a treatable condition might then be missed. The 2021 review therefore advises contacting a national surveillance unit or referral centre for guidance on testing and management.
Sources: Hermann et al., Lancet Neurol 2021 (full text read; a review, and criteria used by surveillance centres may since have been updated); Ng et al., J Neurol 2024 (full text read; UK surveillance data, 2012–2023).
Fatal familial insomnia
In FFI the tests behave differently, as the points below show.
- Overnight sleep study. Records brain waves, breathing and movement through the night, and shows the typical loss of deep sleep.
- Specialised brain scan (PET). Shows reduced activity in the thalamus, the area FFI attacks first — but not in everyone: in the pooled series, 33 of the 42 patients scanned (79%) had it, so a normal scan does not rule FFI out.
- Spinal fluid test (RT-QuIC). This test detects most forms of prion disease but often misses FFI, so a negative result does not rule it out. In one 2026 research study, an experimental version picked up three in four FFI cases, against one in five with the comparison method. That version is not necessarily available in routine laboratories.
- Genetic blood test. Finds the gene change; together with the clinical picture, this establishes the diagnosis. It matters because the FFI gene change does not always produce the classic sleep picture: some carriers have an illness that looks like CJD, on scans and at the bedside.
In the UK, doctors can refer any suspected prion disease to the National Prion Clinic in London, which contacts the referring team within days and can arrange a visit, a video assessment or remote advice. Referral is made by a clinician, so anyone worried about symptoms should start with their GP or treating team. Relatives who are thinking about a genetic test for themselves are advised to see a genetic counsellor first, because a result cannot be taken back.
Mistaken for other dementias
Prion disease is often mistaken for something else at first, including Alzheimer's disease, depression, a stroke or an infection of the brain. In one study of autopsy-confirmed sporadic CJD (not an FFI-specific group), only about one patient in five was diagnosed correctly at their first assessment, and on average the right diagnosis came about eight months after symptoms began.
Someone with a long-standing, typical Alzheimer's diagnosis is very unlikely to have prion disease, which is far rarer and usually progresses over months rather than years. The signs that should raise the question are decline over weeks or months, jerking movements, unsteadiness or visual problems, onset at a younger age, and a family history of rapid dementia or unexplained neurological illness. Some inherited forms progress more slowly and are harder to tell apart.
New blood tests for Alzheimer's are coming into use. One of them, p-tau217, is also raised in prion disease, so a single abnormal result should not be taken as proof of Alzheimer's.
Sources: National Prion Clinic; NPC counselling and support; Zhang et al. 2022 (family history); Paterson et al. 2012; Coysh et al. 2026.
Can it be picked up before symptoms?
Not reliably, for FFI. Researchers in London and Boston have followed healthy carriers of prion gene changes for years, taking blood and spinal fluid samples to look for early warning signs. For one gene change (E200K, a cause of genetic CJD) the RT-QuIC test turned positive one to three years before symptoms in a few people. For the FFI change, no test has been shown to work before symptoms. Results in people who are already ill are mixed: the London cohort could not find test conditions that detected it, while some other studies, using different methods, report that it can be detected once symptoms have begun, so whether a test works seems to depend on the method. Blood markers of nerve damage stayed flat in FFI carriers and rose sharply only around the time symptoms began. So there is at present no test that tells an FFI carrier that illness is approaching. This is one reason researchers favour preventive trials that start treatment in healthy carriers, measuring the drug’s effect on prion protein in spinal fluid rather than waiting for warning signs.
More detail test performance, misdiagnosis studies and blood markers
Sporadic CJD: how the tests perform. The 2021 review (full text read) reports the following. CSF RT-QuIC has a specificity of 99–100% in retrospective and prospective studies; sensitivity was 73–89% with the first-generation assay and 92–97% with the second. The authors note that some apparent false positives may be unrecognised prion disease, but two autopsy-verified non-CJD cases with a positive result have been reported, one of them steroid-responsive encephalitis, itself a CJD mimic. Sensitivity is very high in the commonest subtypes (MM1/MV1 and VV2), lower in MV2 (75–93%), and substantially lower in VV1 and in the cortical type of MM2 (small series: 0–100% and 44–78%); it is poor in sporadic fatal insomnia. In inherited disease it is high for E200K and V210I and low for FFI. RT-QuIC on olfactory-mucosa brushings and skin biopsies has been reported at 89–100% sensitivity in small studies. CSF 14-3-3: a 2012 meta-analysis gave sensitivity 92% and specificity 80%; sensitivity is lower in MV2 and MM2 (about 60–70%) and in early disease, and specificity ranged from 40% to 92% depending on the control group. CSF total tau: sensitivity and specificity about 90% each in most studies, but cut-offs vary (1,072 to 1,400 pg/mL) and it was not formally part of case definitions; in one general neurochemical laboratory, CJD accounted for only 18% of patients with highly raised tau (above 1,200 pg/mL). MRI sensitivity is reported at around 80% and at 92–98%, specificity 74–98%. EEG periodic sharp-wave complexes: sensitivity 64% and specificity 91% in older studies, 39–45% sensitivity in recent comparisons with CSF markers. There is no highly specific blood test comparable to CSF RT-QuIC; blood total tau and neurofilament light are candidates for triage. The authors recommend that a positive RT-QuIC allow a “probable” classification early, even with a single cardinal symptom, while stressing that RT-QuIC cannot distinguish between forms of prion disease and has limited availability outside countries with surveillance programmes.
Sporadic CJD with a negative RT-QuIC (UK). In the national surveillance cohort (250 autopsy-confirmed sporadic cases, 2012–2023; first-generation assay), the 27 RT-QuIC-negative cases had a median age at onset of 62 years against 68, and a median duration of 10.5 months against 4.4. They were less likely to present with gait difficulty (73% against 93%) and more likely to present with sleep disturbance (15% against 2%). VV1 made up 32% of negative cases against 1% of positive ones, and MM2 21% against 3%. MRI was abnormal in 96% of the negative group and EEG in 30%; CSF 14-3-3 was positive in 48% against 75%. Severe co-existing brain pathology of another kind (mostly Alzheimer-type amyloid or tau) was found in 9 of 27 (33%), with no comparison group. The authors point to selection bias (autopsied cases), incomplete genetic testing (37% of negative cases) and use of the older assay as limitations.
Hermann P et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol 2021 (full text read). Ng D et al. Characterisation of RT-QuIC negative cases from the UK National CJD Research and Surveillance programme. J Neurol 2024 (full text read).
Polysomnography shows loss of slow-wave sleep and of sleep spindles, with motor and autonomic overactivation; these are older descriptions from the clinicians who first characterised the disease. The 2026 review led from the National Prion Clinic lists the same picture in its summary of FFI test findings: loss of slow-wave sleep, fragmentation of REM sleep, and loss of sleep spindles and K-complexes, with sympathetic and parasympathetic dysregulation on autonomic testing and thalamic hypometabolism on FDG-PET. It adds that polysomnography is useful in telling FFI apart from other causes of severe insomnia, and notes that people with severe insomnia can sometimes become convinced they have FFI without any clinical signs or markers of neurodegeneration. FDG-PET shows hypometabolism most marked in the mediodorsal and anterior thalamic nuclei and the pulvinar — though that subnuclear pattern rests on a single PET/MRI study of five FFI patients against ten controls, in which hypometabolism was not confined to the thalamus but also appeared in the basal ganglia and widely across the forebrain cortex. In the pooled series, thalamic hypometabolism was present in 33 of 42 patients scanned (78.6%), and CSF 14-3-3 was positive in only 20 of 58 tested (34.5%). CSF RT-QuIC sensitivity is lower for FFI than for sporadic CJD; in one 2026 research study (32 FFI patients; the genotype is not stated in the text read) it rose from 19% to 75% when a full-length human E200K PrP substrate replaced the hamster-sheep comparison substrate. This does not establish the same performance in routine laboratories, and a negative result does not exclude FFI. PRNP sequencing identifies the causative variant.
Rhoads DD et al. Diagnosis of prion diseases by RT-QuIC. Neurology 2020. Correia A et al. Full-length human E200K RT-QuIC substrate. Acta Neuropathol Commun 2026. Xie K et al. Structuro-metabolic pattern of thalamic subnuclei in FFI. Neuroimage Clin 2022 (full text read; 5 patients, 10 controls). Montagna P et al. Familial and sporadic fatal insomnia. Lancet Neurol 2003;2(3):167–76 (abstract read; full text not available to us). Gambetti P, Lugaresi E. Conclusions of the Symposium. Brain Pathol 1998;8(3):571–575 (abstract read; PubMed Central holds no body text for this item). It states that the FFI sleep disorder can be established, or excluded, only by polysomnography. Mead S et al. Genetic causes and modifiers of prion diseases. Lancet Neurol 2026;25(2):181–194 (full text read; Figure 3 and the differential-diagnosis section).
Mistaken for other dementias
In 97 autopsy-confirmed sporadic CJD patients seen at one US referral centre between 2001 and 2007, common initial misdiagnoses included viral encephalitis, paraneoplastic disorder, depression, vertigo, Alzheimer's disease and stroke, each patient collecting an average of 3.8 other diagnoses first. Seventeen (18%) were diagnosed correctly at first assessment, 16 of those by a neurologist, and mean time from onset to diagnosis was 7.9 months — about two-thirds of the way through the illness. Being a specialist referral series, it will overstate how tangled the average path is.
Misdiagnosis runs both ways, and the other direction is the more actionable. Of 1,106 brain autopsies referred to the US surveillance centre as suspected CJD, 352 (32%) were prion-negative. Among the 304 of those with tissue adequate for analysis, the commonest findings were Alzheimer's disease (154, 50%) and vascular dementia (36, 12%) — but 71 (23%) had a potentially treatable disorder: immune-mediated (26, including CNS angiitis, limbic encephalitis and neurosarcoidosis), neoplastic (25, mostly CNS lymphoma), infectious (14) or metabolic (6, including Wernicke encephalopathy). CSF 14-3-3 was positive in more than half of those tested in that treatable group, so a positive 14-3-3 alongside rapidly progressive dementia is not sufficient for a CJD diagnosis.
Plasma p-tau217 and p-tau181 are raised in prion disease regardless of Alzheimer co-pathology, so a single abnormal p-tau result risks misclassifying prion disease as Alzheimer's. In a National Prion Clinic cohort (204 prion disease, 33 Alzheimer's, 41 controls), p-tau217 discriminated poorly (AUC 0.61), while the NfL/p-tau217 ratio discriminated very well in that research cohort (AUC 0.996; 0.986 in an independent validation set of sporadic CJD and Alzheimer's patients). The authors suggest it as a flag to consider prion disease. It is promising research evidence — the journal rates it Class II — not a stand-alone diagnostic test: the validation set did not include inherited prion disease, and the authors note that frontotemporal dementia and motor neurone disease may also raise the ratio, so a high value is a prompt to consider prion disease rather than a diagnosis of it. Under the blood A/T/N scheme, about a quarter of the prion disease cases in this cohort would have been classed A+T+N+, that is, as Alzheimer's.
The FFI genotype can itself be mistaken for sporadic CJD. A 2026 case report describes a 59-year-old D178N-129MM carrier with two months of rapid cognitive and language decline, extensive cortical DWI ribboning, positive CSF 14-3-3 and positive skin RT-QuIC, but no prominent early insomnia; the authors found six earlier D178N-129MM reports with similar cortical or cortical-striatal changes and conclude that the MRI pattern alone should not be used to infer the phenotype. In Japan’s national prion registry, 1 of 10 D178N patients (10%; 95% CI 1.8–40.4%) would have met the criteria for probable sporadic CJD had PRNP not been tested, against 83% of E200K patients; the D178N figure rests on very small numbers.
Separately, Alzheimer amyloid-β can propagate in a prion-like way: iatrogenic Alzheimer's disease has been described in recipients of cadaveric pituitary-derived growth hormone. There is no suggestion of transmission in everyday life.
Paterson RW et al. Differential diagnosis of Jakob-Creutzfeldt disease. Arch Neurol 2012. Chitravas N et al. Treatable neurological disorders misdiagnosed as CJD. Ann Neurol 2011. Coysh T et al. Performance of Alzheimer disease plasma biomarkers in patients with prion diseases. Neurology 2026. Banerjee G et al. Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone. Nat Med 2024; JAMA Neurol 2026. Wei et al. D178N-129MM prion disease: Creutzfeldt-Jakob disease-like cortical ribboning without prominent early insomnia. Front Neurosci 2026 (abstract read; single case with literature review). Kosami et al. Potential misclassification of probable sporadic Creutzfeldt-Jakob disease diagnosed without PRNP testing. J Neurol Sci 2026 (abstract read).
Biomarkers before onset in carriers
In the London National Prion Clinic cohort (648 CSF and plasma samples, including 16 carriers sampled while healthy who later developed inherited prion disease, two of them FFI), second-generation RT-QuIC detected presymptomatic seeding only in E200K carriers. No RT-QuIC conditions were found for D178N-129M despite extensive exploration; symptomatic D178N-129M CSF was negative, and at-risk D178N-129M and 129V samples were negative with bank vole RT-QuIC. Other studies report detection in symptomatic FFI with different methods: 24 of 32 samples with a full-length human E200K substrate in a 2026 study (Correia et al., see Diagnosis), and 12 of 12 in an older Japanese series (PLoS ONE 2013;8:e54915, abstract only read). The results conflict and appear to depend on the assay. Plasma GFAP and NfL behaved as “proximity markers” in slowly progressive forms such as P102L, with GFAP rising before NfL, but in the fast forms (E200K and D178N-FFI) the curves were flat and rose abruptly close to onset; the authors state that neither marker appeared helpful in identifying D178N-129M carriers nearing conversion. In the Massachusetts General Hospital cohort (41 carriers, 7 of them D178N, 21 controls, followed up to six years), RT-QuIC turned positive 1 to 3.1 years before onset in three E200K converters, with the interval apparently shorter in a codon 129 VV than in two MV individuals; plasma NfL rose in all four converters but not remarkably relative to age or baseline, and no D178N carrier converted during follow-up. CSF total PrP was stable within individuals (mean coefficient of variation about 9%) for up to six years, including at RT-QuIC-positive time points, which is why it is proposed as the readout for PrP-lowering drugs in healthy carriers and why “primary prevention” trials, rather than waiting for prodromal markers, are argued to be the tractable design. One caution for interpreting NfL: a course of the antibiotic minocycline raised plasma and CSF NfL several-fold in a healthy at-risk participant with no other biomarker change, apparently by slowing its clearance rather than by causing nerve damage.
A 2026 German study measured prion protein itself in 136 plasma and 84 CSF samples. Plasma PrP was significantly lower in both symptomatic and asymptomatic D178N carriers than in healthy controls, and separated asymptomatic D178N carriers from controls with high accuracy (AUC 0.96); CSF PrP was lower in symptomatic D178N patients. This is a persistent group difference in carriers, not a sign that onset is approaching, and it is consistent with the stable within-person CSF PrP reported from Boston. The authors’ point is that baseline PrP differs by mutation, which matters when PrP is used to measure the effect of PrP-lowering drugs.
Mok TH et al. Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease. Brain 2023 (full text searched; D178N and FFI passages read). Vallabh SM et al. Fluid biomarkers in individuals at risk for genetic prion disease up to disease conversion. Neurology 2024 (abstract and D178N passages read). Thompson AGB et al. Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. Mol Psychiatry 2021 (abstract and D178N passages read). Vallabh SM et al. Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. BMC Med 2020 (abstract). Gentile JE et al. Evidence that minocycline treatment confounds the interpretation of neurofilament as a biomarker. Brain Commun 2025 (abstract). Laginha et al. Prion protein (PrP) profiles in blood and CSF: insights into pre-symptomatic and symptomatic prion disease. Brain Commun 2026 (abstract read).
Treatments and trials
There is no proven treatment yet. Earlier drugs tried in patients, including quinacrine, doxycycline and pentosan polysulfate, have not shown clinical benefit. Doxycycline was tested in two randomised, double-blind, placebo-controlled trials in sporadic CJD: one of 121 patients at an advanced stage, stopped when an interim analysis found no difference in survival, feeding or akinetic mutism, and a second of 13 patients at an earlier stage, also negative.
For CJD, care focuses on comfort and on planning ahead: treating symptoms such as pain, anxiety and muscle jerks, with a specialist team working alongside the local care team. A 2026 systematic review of 30 studies of sporadic, iatrogenic and variant CJD (inherited forms were left out) found that the symptoms reported most often were jerking movements (myoclonus), problems with balance and coordination, and psychiatric symptoms including hallucinations, depression and anxiety. It also found that no study had measured quality of life, that little was known about social and spiritual needs, and that good evidence on managing symptoms at the end of life is lacking. Early palliative care is thought to be important, but because the disease is so rare, many palliative-care teams meet few patients with it.
Source: Williams et al., BMC Palliat Care 2026 (full text read).
The approach now being tested is different: lower the amount of prion protein in the brain, so there is less available to misfold. There are reasons to investigate it: mice without the protein survive (though they develop a peripheral nerve problem), and some healthy older people naturally make only half the usual amount. In animals, lowering it has slowed the disease markedly. None of this shows that long-term lowering is safe in people.
Three ways of doing this are in development:
- Antisense drugs, short man-made genetic strands that block the protein's instructions. Being tested in people (ION717).
- siRNA drugs, a related approach that destroys the instructions. Being tested in people (PRiSM, whose drug a 2026 review calls Prionsiran), with a second (ALN-6457) due to start.
- Gene editing, a one-off change to the gene itself. Tested only in mice so far.
An older approach, an antibody that sticks to the prion protein (PRN100), was given to six patients with CJD in London in 2018–19. It appeared safe, but all six continued to decline, and a programme that small cannot show whether a drug works. No trial of it is registered.
Separately, a larger trial in China is testing efavirenz, an existing HIV drug, against placebo in people with CJD, to see whether it prolongs survival. It works differently, by helping the brain clear cholesterol, and so far has been tested only in mice.
The prion-lowering trials are early-stage studies. They are designed to show whether the drugs are safe and reach their target, not yet whether they work. Mouse experiments suggest existing protein clears over days to weeks, so any benefit in people may take time to appear; the human time course is not known. Researchers believe the best chance lies in treating people with a known gene change before symptoms begin, and PRiSM is the first trial to include such people.
Source for care: NHS: CJD treatment. Source for earlier drugs: National Prion Disease Pathology Surveillance Center.
More detail how the drugs work and how fast the protein clears
Current candidates reduce PrP synthesis: antisense oligonucleotides and divalent siRNA, both given intrathecally, and preclinical one-time base editing. Existing PrP then clears with its own half-life, which the authors estimate at 5–6 days in mouse brain (4.8 to 6.4 days across their methods), so after an antisense dose the protein does not reach its lowest level until about four weeks. They state that they have not studied the half-life of PrP in humans, and suggest the lag may if anything be shorter in genetic prion disease. This is a mechanism-based inference from animal data, not an established human time course.
Names and status in the 2026 review. The review led from the National Prion Clinic (published February 2026) lists the PrP-targeting therapies in development. Three entries need reading against later events. (1) It names the Broad Institute’s divalent siRNA “Prionsiran (di-RNA-2439s4)”, “being developed by patient–scientists”. This is the PRiSM drug; the registry calls it “PrP-siRNA” and the NIH network running the trial calls the study NN112. No other source we found uses the name Prionsiran. The review cites the mouse work as a bioRxiv preprint (2025); it has since been published in Nucleic Acids Research (Gentile et al. 2026, on the reading list). (2) It describes ALN-6457 as “in preclinical development”. That is now out of date: Regeneron registered a Phase 1/2 trial in October 2026 (see the table). (3) For the anti-PrP monoclonal antibody PRN100 it reports an open-label evaluation in six patients. That programme (UCLH, October 2018 to July 2019, under a Specials Licence) gave intravenous PRN100 to six patients with probable CJD for 7 to 260 days: it was well tolerated, reached the target CSF concentration in four, and showed some drug-related changes at autopsy in two, but all six declined on the MRC scales. The authors call for formal efficacy trials; no PRN100 trial was found on ClinicalTrials.gov (searched 2 November 2026). The CJD Foundation lists it as “not currently enrolling”.
A 2026 mouse study adds a safety caution for antisense drugs. Some, but not all, gapmer antisense oligonucleotides injected into spinal fluid caused fatal subacute toxicity in mice at a late stage of prion disease, but not in uninfected mice. The effect depended on the compound and the disease stage, was not predicted by tests in healthy animals, and was linked to a shared drop in a set of astrocyte genes; the authors interpret it as an interaction between particular compounds at high doses and advanced disease. The abstract does not name the compounds or say whether ION717 was among them. This is an animal finding, not evidence about the human trials.
Corridon TL et al. PrP turnover in vivo. PLoS Pathog 2026 (full text read). Lavigna G et al. Doxycycline rescues recognition memory and circadian motor rhythmicity but does not prevent terminal disease in fatal familial insomnia mice. Neurobiol Dis 2021;158:105455 (full text read) — also the source for the two negative randomised doxycycline trials in sporadic CJD noted above. Zhao Y et al. Antisense oligonucleotides that are toxic to prion-infected mice share an emergent mechanism. Nucleic Acid Ther 2026 (abstract read). Mead S et al. Genetic causes and modifiers of prion diseases. Lancet Neurol 2026 (full text read; Table 2). Mead S et al. Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease. Lancet Neurol 2022;21(4):342–354 (abstract read). NeuroNEXT: NN112 PRiSM. CJD Foundation: drug development (checked 1 November 2026).
| Trial | What it tests | Evidence so far | Status |
|---|---|---|---|
| ION717 / PrProfile Ionis · NCT06153966 | Antisense drug to lower prion protein. People with early symptoms only. | First-in-human safety trial, placebo-controlled in its first two dose regimens; 85 participants (ClinicalTrials.gov, checked 19 November 2026). No results published. The EU register (CTIS 2023-503355-98-00, checked 19 November 2026) lists 36 planned participants and recruitment ended. CureFFI reported that the first two regimens filled at 56 participants in December 2024. The rise to 85 is consistent with the third regimen adding 29 (our arithmetic; the sponsor has not stated the split). The EU entry (CTIS, checked 19 November 2026) gives 36 as the planned total for the whole trial, of which 8 are in the EU/EEA across four sites, so it looks not to have been updated as the trial grew. Why it was lower than the 56 on ClinicalTrials.gov from the outset is not explained. | Active, not recruiting A third, open-label group was added in March 2026 (CureFFI; the registry now describes it). Ionis told the patient community on 25 August 2026 that the trial was no longer taking new participants, that enrolment should complete soon, and that ION717 is not available outside the trial. Thirteen sites in Europe, North America, Japan, Israel and Australia (Royal Melbourne Hospital); none in the UK (rechecked 19 November 2026) |
| PRiSM NCT07444580 · Broad Institute of MIT and Harvard | Divalent siRNA to lower prion protein, given as a single dose. Open to people with symptoms and to people at genetic risk who have no symptoms. | First human safety trial, started May 2026. Positive results in mice. No human safety or efficacy results yet. | Recruiting Five US sites only (rechecked 19 November 2026). The Prion Alliance announced on 14 October 2026 that the arm for people at genetic risk without symptoms is now open. That arm needs a predictive genetic test showing a highly penetrant PRNP variant and normal neurological and cognitive scores (registry: MRC Scale 20, MoCA 24–30); people with symptoms must be no more than moderately impaired. Funded by the NIH NeuroNEXT network. Enquiries: priontrials@broadinstitute.org |
| ALN-6457 Regeneron · NCT07832370 | siRNA drug to lower prion protein, given in repeated doses. Adults with sporadic CJD or genetic prion disease who have symptoms but can still understand and complete the trial questionnaires; BMI under 35. The registry does not state how it is given, but its exclusion criteria and spinal-fluid measurements refer to lumbar puncture. Press reports describe it as a C16-lipid-conjugated siRNA from the Regeneron–Alnylam partnership; no sponsor publication confirming this was found (checked 29 October 2026). | Phase 1/2 open-label trial, 60 participants, follow-up to 2031. Change in blood neurofilament light is a primary outcome alongside safety, so it is also looking for a signal of slowed damage. | Not yet recruiting ClinicalTrials.gov: start date 23 October 2026, still not yet recruiting, no sites listed (rechecked 19 November 2026). The EU register (CTIS 2026-526727-21-00, checked 19 November 2026) shows the trial authorised on 29 October 2026 with one site (UZ Leuven, Belgium), recruitment pending; it plans 48 participants (4 in Belgium, 44 outside the EU) against 60 on ClinicalTrials.gov, and the ClinicalTrials.gov start date is earlier than the EU authorisation. Brazilian press reported in September 2026 that the medicines regulator, Anvisa, authorised import of the drug for one patient under a compassionate-use programme. A single patient treated outside a trial cannot show whether a drug works or is safe. Access outside the trial: the patient group CJDISA (23 September 2026) points families to Regeneron’s general managed access policy (May 2026). Under it, only the treating doctor can apply, through Regeneron’s online portal, for a patient with a serious condition who cannot join a trial; Regeneron weighs the evidence of benefit and risk, regulatory approval in the patient’s country, and whether supply would hold up the drug’s development. Access is not guaranteed, and the policy does not mention prion disease or ALN-6457. |
| DOXIFF Mario Negri Institute · NCT04846335 | Doxycycline, 100 mg/day, doubled to 200 mg from May 2019 after an interim safety review, given to healthy D178N carriers aged 44–53 to see whether it prevents or delays onset. Primary outcome: survival at ten years. | In FFI mice, presymptomatic doxycycline rescued recognition memory, restored circadian motor rhythmicity and reduced hippocampal microglial activation — but did not delay onset, slow progression or prolong survival. | Completed 30 Nov 2024 No results posted or published as of 19 November 2026: none on ClinicalTrials.gov and none found in PubMed (both rechecked that day). The EU Clinical Trials Register (EudraCT 2010-022233-28, global end of trial 30 Nov 2024) was checked again on 19 November 2026: it lists the trial as completed and the trial results field is empty (on 4 November the results page read “There are no public results”). The researchers expected results in 2023, then by the end of 2024; a May 2025 review by the lead investigator still describes the trial as ongoing. A Telethon fundraising story speaks of promising results but in the same piece says the data had still to be analysed, so it is not evidence of an outcome. Design, per the group’s 2022 account (full text read): 10 carriers took doxycycline and 15 non-carriers took identical placebo tablets, so that no participant learned their genotype; there was no placebo group of carriers. Efficacy is judged against historical data: the trial counts as positive if no more than three of the ten carriers become ill within ten years. The same account reports two cases of the disease among participants by 2022. With ten people treated, any result will be weak evidence either way. The registries disagree: ClinicalTrials.gov lists 29 participants and Phase 2; the EU register lists Phase III, randomised double-blind, 30 planned; the 2022 paper says 25 were enrolled when recruitment closed in April 2013. |
| Efavirenz for CJD Xuanwu Hospital, Beijing · NCT07482085 | Efavirenz, an existing HIV drug taken by mouth (200 mg nightly for a week, then 400 mg), against placebo. Adults aged 18–80 with probable sporadic CJD or genetically confirmed inherited CJD who keep some functional ability (MRC-PDRS above 10). Not a prion-lowering drug: it activates CYP46A1, a brain enzyme that clears cholesterol. Primary outcome: survival from randomisation. | Randomised, double-blind, placebo-controlled Phase 3 trial, 246 participants planned. Evidence so far is from mice only: in mice infected with scrapie prions (Ali et al. 2021) and in mice making human prion protein infected with sporadic CJD prions (Ali et al. 2025), low-dose efavirenz slowed disease and extended survival. No human results. | Recruiting China only. Started 14 April 2026; primary completion December 2028. The registry describes 21 centres nationwide but lists only Xuanwu Hospital, Beijing (checked 19 November 2026). Inherited CJD is included, but the registry does not say whether FFI patients are eligible. |
Trial statuses last checked against ClinicalTrials.gov on 19 November 2026 (ION717, PRiSM, ALN-6457, DOXIFF, efavirenz). The PROSPECT, Massachusetts General Hospital, Tel Aviv and TAPCJD studies below were checked on the same day: all four were recruiting. The EU entries for DOXIFF (EU Clinical Trials Register: completed, no results) and for ION717 and ALN-6457 (CTIS: unchanged) were all checked on 19 November 2026. Recruitment and eligibility change: always confirm on the registry.
Research for family members at risk of inherited prion disease is listed in a closed section at the end of Help and information: If prion disease runs in your family.
Reading list
Start with the two general-reader links, then the Intermediate papers. Each card says who it suits.
Plain-language overview of symptoms, causes and diagnosis.
Information for patients, families and professionals from the UK national referral centre.
Broad overview bridging basic science and the clinic.
The classic review of the prion hypothesis: how misfolded PrP is thought to spread by refolding normal PrP. A review from 1998, so it predates much of the work cited elsewhere on this page.
How the commonest form is diagnosed: scans, EEG, spinal fluid tests and RT-QuIC.
Which symptoms occur in sporadic, iatrogenic and variant CJD, and what is still unknown about care.
Why trials before symptoms matter, and what makes them hard.
Current authoritative review, led from the National Prion Clinic.
Focused review of FFI: symptoms, thalamic damage, tests.
The sleep and autonomic features, from the Bologna group.
Standard genetics reference: inheritance, testing and counselling.
How the DOXIFF trial was designed with an Italian FFI family.
The original design of the DOXIFF trial: carriers over 42 given doxycycline 100 mg a day, compared with historical data (as first planned; the dose was later doubled).
The laboratory work behind the PRiSM trial drug.
Why prion-lowering drugs may take weeks to act.
A one-time gene edit that extended survival in mice. Mouse data only.
Glossary
Terms are in alphabetical order. Each has a plain-language definition. Use “Show technical definitions” to add the technical one beneath each. Type to filter.
- 14-3-3 protein
- A protein that leaks into the spinal fluid when nerve cells are damaged quickly. A raised level supports a diagnosis of CJD but is not specific to it.
- Detected in CSF by Western blot or ELISA; a 2012 meta-analysis gave sensitivity 92% and specificity 80%; false positives occur in acute brain injury and brain inflammation.
- Agrypnia excitata
- Severe sleeplessness with constant restlessness.
- Loss of slow-wave sleep with 24-hour motor and autonomic overactivation and oneiric stupor.
- Allele
- One version of a gene. Everyone carries two copies of PRNP, one from each parent, and each copy is an allele.
- Alternative form of a gene at a locus; PRNP alleles are described by codon 129 and any pathogenic variant, e.g. D178N-129M.
- Amyloid-β
- A protein fragment that forms the plaques found in Alzheimer’s disease.
- Aβ peptides cleaved from amyloid precursor protein; can seed aggregation in a prion-like way.
- Antemortem
- Before death; an antemortem genetic test is one done during life.
- As opposed to post-mortem.
- Antisense oligonucleotide (ASO)
- A short man-made genetic strand that tells cells to make less of a protein.
- Synthetic oligo binding PRNP mRNA to reduce PrP synthesis, e.g. ION717.
- AUC
- A score from 0.5 to 1 for how well a test separates two groups: 0.5 is no better than chance, 1 is perfect.
- Area under the receiver operating characteristic (ROC) curve.
- Autosomal dominant
- One altered copy of the gene is enough; each child has a 50% chance of inheriting it.
- Single-allele inheritance, not sex-linked.
- Base editing
- A one-off edit to the gene itself so less PrP is made.
- In vivo single-nucleotide editing, e.g. installing a stop codon in PRNP; preclinical only.
- Brainstem
- Joins the brain to the spinal cord; runs breathing and heart rate.
- Midbrain, pons and medulla; contains the reticular formation and autonomic centres.
- BSE
- “Mad cow disease”: a prion disease of cattle.
- Bovine spongiform encephalopathy; dietary exposure to it caused vCJD.
- Cerebellum
- At the back of the head; balance, smooth movement and coordinated speech.
- Hindbrain structure coordinating motor control; damage causes ataxia.
- Cerebral cortex
- The wrinkled outer layer of the brain: thinking, memory, speech, vision, voluntary movement.
- Six-layered neocortex covering the cerebral hemispheres.
- CJD (Creutzfeldt-Jakob disease)
- The commonest human prion disease, usually causing rapidly worsening dementia.
- Prion disease classically presenting with rapidly progressive dementia, myoclonus and ataxia; sporadic, genetic, variant and iatrogenic forms.
- Codon
- Three DNA letters that specify one building block of a protein; “codon 178” is the 178th position along the protein.
- Nucleotide triplet encoding one amino acid; PRNP codon numbering follows the protein sequence.
- Codon 129
- A common natural variation in PRNP that shapes how the disease shows itself.
- Methionine/valine polymorphism; with D178N, 129M on the same allele gives FFI and 129V gives genetic CJD.
- Cryo-EM
- Cryo-electron microscopy: flash-freezing samples and imaging them with an electron microscope to work out their 3D structure in close to atomic detail.
- Helical or single-particle reconstruction; RML fibrils resolved to 2.7 Å.
- CSF (cerebrospinal fluid) and lumbar puncture
- The clear fluid around the brain and spinal cord, sampled with a needle in the lower back (lumbar puncture).
- Cerebrospinal fluid; usually sampled at L3/4 or L4/5.
- D178N
- The specific gene change behind FFI.
- PRNP missense mutation, aspartic acid to asparagine at codon 178.
- Demyelinating neuropathy
- Damage to the insulating myelin sheath of nerves outside the brain and spinal cord, slowing their signals.
- Peripheral neuropathy with demyelination; documented in PrP knockout mice.
- Disulfide bond
- A strong chemical link between two sulphur-containing building blocks, holding parts of a protein together.
- Covalent S–S bond between cysteines; in PrP, Cys179–Cys214.
- Dura mater graft
- A graft of the tough membrane around the brain, taken from a donor, once used in brain surgery. Some grafts carried prions.
- Cadaveric dura mater (notably the product Lyodura) caused most graft-related iatrogenic CJD; mean incubation about 12 years.
- Dysautonomia
- Disturbance of automatic body functions: heart rate, blood pressure, sweating, temperature.
- Autonomic dysfunction, chiefly sympathetic overactivity in FFI.
- EEG (electroencephalogram)
- A recording of the brain’s electrical activity, made with electrodes on the scalp.
- Periodic sharp-wave complexes at about 1 per second are typical of sporadic CJD; sensitivity about 64% in older series and 39–45% in recent comparisons.
- Encephalitis
- Inflammation of the brain, usually from infection or an immune reaction.
- Viral (e.g. herpes simplex) or autoimmune; a common CJD mimic.
- Fatal familial insomnia (FFI)
- Inherited prion disease that first attacks sleep, usually from around age 50.
- Genetic prion disease (D178N-129M) with selective thalamic degeneration; mean course about 13 months, shorter in 129MM than 129MV.
- Fibril and amyloid
- Long thread-like stacks of misfolded protein; amyloid is the general name for such deposits.
- Cross-β fibrils; prion fibrils have parallel, in-register intermolecular β-sheets.
- Founder mutation
- A gene change that arose once in a distant ancestor and was passed down to many descendants.
- Inferred where apparently unrelated carriers share a haplotype around the variant.
- Genotype
- The combination of gene versions a person carries; at codon 129 it is MM, MV or VV.
- Codon 129 genotype modifies susceptibility and phenotype; in FFI, 129MM is associated with a shorter course than 129MV.
- Glycan
- A sugar chain attached to a protein.
- N-linked glycans at asparagines 181 and 197 of PrP.
- GPI anchor
- A fatty tail that tethers the prion protein to the outer surface of the cell.
- Glycosylphosphatidylinositol anchor at the C-terminus; “anchorless” PrP lacks it.
- GSS (Gerstmann-Sträussler-Scheinker disease)
- A rare inherited prion disease, usually starting with unsteadiness and running a slower course than CJD, often over several years.
- Genetic prion disease, classically P102L, with cerebellar ataxia and PrP amyloid plaques.
- Half-life
- The time it takes for half of something to be cleared or broken down.
- For PrP in mouse brain, about 5–6 days.
- Haplotype
- A set of gene variants close together on a chromosome that are inherited as a block; used to trace family lines.
- Combination of linked alleles on one chromosome; a shared haplotype suggests descent from a common ancestor.
- Helix and sheet (α-helix, β-sheet)
- Two common shapes a protein chain takes: a coil (helix), and a flat sheet made of strands lying side by side.
- Secondary structure; PrPC is mostly α-helical, PrPSc is rich in β-sheet.
- Hypothalamus
- Below the thalamus; controls hormones, body temperature, hunger and the sleep-wake cycle.
- Diencephalic region regulating autonomic and endocrine function and circadian rhythm.
- Iatrogenic
- Caused by medical treatment.
- Transmitted through medical or surgical procedures, e.g. cadaveric growth hormone, dura mater grafts.
- Intrathecal
- Given by injection into the spinal fluid.
- Delivery into the CSF space by lumbar puncture, bypassing the blood–brain barrier.
- Knockout mouse
- A mouse bred with a particular gene switched off, to study what the gene does.
- Prnp-null mice lack PrP, are viable, resist prion infection and develop late-onset demyelinating peripheral neuropathy.
- Kuru
- A prion disease once seen among the Fore people of Papua New Guinea, spread by the ritual eating of dead relatives. It fell sharply once the practice stopped.
- Acquired prion disease; incubation can exceed 50 years; heterozygosity at codon 129 is protective.
- Limbic system
- Linked brain structures involved in emotion, memory and motivation.
- Includes hippocampus, amygdala and cingulate cortex, with connections to the anterior and mediodorsal thalamus and hypothalamus.
- Misfolding / templating
- A protein taking the wrong shape and passing that shape on.
- Conformational conversion of PrPC to PrPSc on contact with a PrPSc seed.
- Molecular simulation
- Computer modelling of how a protein’s atoms move, to predict how its shape changes.
- Molecular dynamics; metadynamics is an enhanced-sampling method for exploring conformational change.
- MRI (diffusion-weighted)
- A brain scan that uses magnets rather than X-rays. A special setting shows areas where nerve cells are under stress.
- DWI and ADC sequences; cortical “ribboning” and restricted diffusion in the caudate and putamen are typical of sporadic CJD; the pulvinar sign points to vCJD.
- Myelin
- The fatty insulating sheath around nerve fibres that speeds up signals.
- Made by Schwann cells in peripheral nerves and oligodendrocytes in the brain and spinal cord.
- NfL (neurofilament light)
- A structural protein released when nerve cells are damaged. Blood levels show how much active damage there is, whatever the cause.
- Neurofilament light chain; non-specific marker of neuroaxonal injury, very high in prion disease.
- Non-REM and slow-wave sleep
- Non-REM sleep is the dreamless part of sleep; its deepest stage, slow-wave sleep, is when the brain is hardest to wake.
- NREM stages N1–N3; N3 (slow-wave sleep) shows high-amplitude delta activity on EEG.
- Notifiable disease
- A disease doctors are required by law to report to public-health authorities.
- NOIDS is the Notifications of Infectious Diseases reporting system.
- Nucleation
- The slow first step in which a small stable cluster forms; once it exists, growth is fast, as ice crystals grow around a speck.
- Rate-limiting formation of a critical nucleus; added seeds bypass the lag phase.
- Oligomer
- A small cluster of a few protein molecules stuck together.
- Small multimeric assembly; in nucleation models a stable oligomeric nucleus is needed for propagation.
- Oneiric stupor
- A dream-like state in which the person seems awake but drifts into dreams and may act them out.
- Subwakeful state with enacted dream content, characteristic of agrypnia excitata.
- Open-label
- Everyone knows which treatment is being given; there is no placebo or blinding.
- Unblinded design without placebo control, so effects are harder to attribute to the drug.
- p-tau217
- A form of the protein tau, measured in blood as a marker of Alzheimer’s. It is also raised in prion disease.
- Tau phosphorylated at threonine 217.
- Paraneoplastic disorder
- Nervous-system damage caused by the immune system reacting to a cancer elsewhere in the body.
- Onconeural antibody-mediated syndromes (e.g. anti-Hu, anti-Ma2); can mimic rapidly progressive dementia.
- Penetrance
- How likely someone with the gene change is to develop the disease.
- Proportion of carriers who become affected; very high for D178N.
- PET scan
- A scan using a small dose of radioactive tracer to show how active each part of the brain is.
- FDG-PET measures regional glucose uptake; reduced uptake (hypometabolism) indicates reduced neuronal activity.
- Phase 1 / Phase 1/2 trial
- The earliest trials in people, testing mainly safety and dose in small groups. Phase 1/2 also looks for early signs of effect.
- Phase 1: first-in-human safety, tolerability and pharmacokinetics; Phase 2: preliminary efficacy and dose-finding.
- Polymorphism
- A common, normally harmless natural variation in a gene.
- Sequence variant common in the population; e.g. PRNP M129V.
- Polysomnography
- An overnight sleep study.
- Multi-channel recording of EEG, eye, muscle and breathing during sleep.
- Presymptomatic
- Before any symptoms appear.
- Carrier with no clinical signs.
- Prion
- A misfolded form of PrP that makes normal copies misfold too. The word comes from “proteinaceous infectious particle”.
- Self-propagating misfolded PrP (PrPSc), the causal agent of prion disease. Term coined by Prusiner in 1982.
- Prion protein (PrP)
- A normal protein found on nerve cells; its job is not fully understood.
- Glycoprotein encoded by PRNP; the normal form is written PrPC.
- Prion strain
- A distinct variety of prion, with its own misfolded shape, that produces a characteristic pattern of disease.
- Conformationally distinct PrPSc assemblies with heritable phenotypes; RML, ME7 and 263K are rodent-adapted laboratory strains.
- PRNP
- The gene that carries the instructions for making PrP.
- Prion protein gene, chromosome 20.
- Protein folding
- How a protein’s chain of building blocks curls up into the shape it works in.
- Acquisition of native structure. PrPC has an unstructured N-terminus (residues 23–127) and a folded C-terminal domain (128–231) of three α-helices and a short β-sheet.
- Recombinant protein
- Protein made in the laboratory, usually by bacteria given the gene, rather than taken from tissue.
- E.g. bacterially expressed PrP without glycans or GPI anchor; used in stability studies and as RT-QuIC substrate.
- Residue
- One building block (amino acid) in a protein chain; “residues 23–127” means positions 23 to 127.
- Amino acid residue, numbered from the N-terminus.
- Reticular formation
- A network of nerve cells running through the brainstem that controls alertness, sleep and waking.
- Diffuse brainstem network including the ascending arousal system; also regulates autonomic and motor tone.
- RT-QuIC
- A very sensitive lab test that detects prions in spinal fluid.
- Real-time quaking-induced conversion seeding assay; lower sensitivity in FFI than in sporadic CJD.
- RT-QuIC substrate
- The normal lab-made prion protein added to an RT-QuIC test, which misfolds if prions are present in the sample.
- Recombinant PrP (e.g. hamster–sheep chimera, or full-length human E200K) seeded by PrPSc in CSF; the choice affects sensitivity.
- Sensitivity (of a test)
- The proportion of people with a disease whom a test correctly detects.
- True-positive rate; low sensitivity means a negative result does not exclude disease.
- siRNA
- A related approach that switches off the gene's message. “Divalent” siRNA joins two such molecules together, which helps the drug spread through and stay in brain tissue.
- Short interfering RNA directing degradation of PRNP mRNA, e.g. the PRiSM drug.
- Sleep spindles
- Brief bursts of brain-wave activity during light sleep, generated by the thalamus.
- 11–16 Hz bursts characteristic of N2 sleep, generated by the thalamic reticular nucleus; lost in FFI.
- Sporadic
- Arising without an identified cause or inherited gene change; a family history alone does not settle it.
- No disease-associated PRNP mutation or acquired exposure identified; about 85% of human prion disease.
- Sporadic fatal insomnia
- The same illness without the gene change; extremely rare.
- Sporadic prion disease with an FFI-like phenotype and no PRNP mutation.
- Thalamic nuclei
- Distinct clusters of nerve cells within the thalamus, each with its own connections.
- Mediodorsal (prefrontal and limbic links), anteroventral (limbic circuit with hippocampus and cingulate) and pulvinar (visual and association cortex); mediodorsal and anteroventral degenerate earliest in FFI.
- Thalamus
- Deep brain hub that relays signals and helps control sleep.
- Mediodorsal and anteroventral nuclei are principally affected in FFI.
- Thermodynamic stability and kinetic trap
- A shape is thermodynamically stable if it is the protein’s most settled, lowest-energy form. A kinetic trap is a less stable shape the protein stays in because changing out of it is very slow.
- Free energy governs equilibrium; a high activation barrier can hold a protein in a metastable state.
- Truncating variant
- A gene change that stops the protein being made in full, so that copy produces little or no working protein.
- Nonsense, frameshift or splice variant causing premature termination; loss of function.
- UKHSA
- UK Health Security Agency, which replaced Public Health England in 2021.
- The public-health agency for England; it runs the NOIDS notification system.
- Variably protease-sensitive prionopathy (VPSPr)
- A very rare prion disease, mostly in people around 70, in which the misfolded protein is easier to digest in the laboratory than in CJD.
- Estimated 2–3 per 100 million per year; median onset about 70 years, duration about 2 years; codon 129 distribution differs from that of sporadic CJD.
- Variant CJD (vCJD)
- A form of CJD caught from eating beef infected with BSE. It mainly affected younger people.
- Acquired prion disease caused by the BSE prion strain; first described in the UK in 1996.
Help and information
In the UK
- National Prion ClinicLondon. The NHS national referral centre, with information for patients and professionals. Referrals are made by clinicians.
- CJD services, University of EdinburghHome of the UK reference laboratory for the spinal fluid test (RT-QuIC) and specialist pathology advice. Clinical advice on suspected cases now goes through the National Prion Clinic, which also advises clinicians on where to send samples (the route depends on the test).
- CJD Support NetworkUK charity for patients, families and carers, with a helpline (0800 774 7317; check opening hours with the charity).
- Prion Alliance and CureFFI.orgClear, research-led explanation of the science, from researchers at the Broad Institute.
- Cure CJD CampaignA fund within UCLH Charity supporting prion research at UCL.
In Australia
- Australian National CJD RegistryMelbourne. Runs national surveillance of human prion disease and provides diagnostic testing. Suspected cases are notified to the Registry and to the state or territory health department.
- CJD Support Group NetworkSupport, information and advocacy for Australians affected by CJD or other prion diseases, including people with a genetic predisposition. 24-hour hotline: 1800 052 466. Email: contactus@cjdsupport.org.au
- Australian Government: CJDHow CJD is defined and monitored in Australia as a nationally notifiable disease, with the national infection control guidelines.
In other countries
- CJD International Support Alliance: Global SupportA directory of patient and family associations in about 20 countries, including Canada, Germany, Italy, Spain, Portugal, India, Japan and New Zealand. The directory is not dated, so check each association’s own site for current contact details.
If prion disease runs in your family research for relatives at risk, and precautions over giving blood and surgery
This part is for readers whose family has an inherited form of prion disease. It reports published research and official guidance and is not advice. Please speak to the National Prion Clinic or your clinical genetics service before acting on any of it.
Research for family members at risk
In the UK: the National Prion Monitoring Cohort, run by the National Prion Clinic and UCL, includes people without symptoms who are at risk of inherited prion disease, FFI included. One strand is for people who have tested positive; another is for people at significant risk without a confirmed diagnosis, such as relatives in a family where a gene change has been found.
- Check-ups every 6 to 12 months, at your choice, in London or at home if you live far away.
- A neurological examination each time; memory tests, scans and a blood sample are optional and can be declined.
- Travel, a hotel and meals are paid for you and up to two relatives. No treatment is given: the aim is to prepare for testing future drugs.
- The information sheet says no DNA testing is done on study blood samples, so taking part does not appear to mean learning your own genetic status. It does not say outright whether relatives who have never had a gene test can join. The clinic’s own researchers, however, describe the cohort’s at-risk group since 2008 as including both confirmed carriers and untested blood relatives of people affected by, or known to carry, a disease-causing gene change (Mok et al., Brain 2023). So untested relatives have taken part, and the National Prion Clinic has confirmed that this still applies: at-risk people who have not had a gene test are eligible (email reply to an enquiry from this page, 5 November 2026).
Contact: Professor Simon Mead, National Prion Clinic. Phone 020 7679 5142 or 020 7679 5036; email uclh.prion.help@nhs.net. Information sheets revised July 2026; ethics approval renewed September 2024 (HRA summary).
In the US: the PROSPECT registry (Case Western Reserve University, with the CJD Foundation and Prion Alliance) follows symptom-free adults at risk of genetic prion disease (carriers or not yet tested) for up to ten years, and a Massachusetts General Hospital biomarker study (NCT05124392, registry completion date June 2027) recruits carriers, relatives and volunteers without the variant. Both are US-based; PROSPECT is open to US residents only.
Two further observational studies (neither tests a treatment; both recruiting, checked on ClinicalTrials.gov on 19 November 2026; no results published for either):
- Natural history of preclinical genetic CJD (Tel Aviv Sourasky Medical Center, Israel; NCT05746715). Healthy first-degree relatives, aged 50 or over, of people with genetic CJD caused by the E200K variant, whether or not they carry it, who are willing to have genetic testing. Yearly visits include brain MRI, a lumbar puncture, blood and urine tests and a sleep study; the main measure is whether misfolded prion protein can be detected in spinal fluid by RT-QuIC before symptoms. 126 planned; started June 2022; primary completion December 2028. It is limited to E200K families, so it does not apply to FFI.
- Teleneurology Assessment Program for CJD (TAPCJD) (University Hospitals Cleveland Medical Center, with Case Western Reserve University and the CJD Foundation; NCT07840547). For people who already have probable or definite prion disease, or a known PRNP variant with active disease, and a study partner who is with them for each video visit. Follow-up is by secure video assessments of symptoms, thinking, function and caregiver wellbeing, to describe the course of the illness and test remote assessment. 200 planned; started January 2022; completion January 2032. The only listed site is Cleveland; the registry does not say whether people outside the US can take part.
Relatives at risk are also asked to take some precautions over giving blood, donating organs and telling doctors before operations: see the guidance below.
For blood relatives in the UK: giving blood, donating organs and having operations
Blood relatives of someone with an inherited prion disease, FFI included, may be asked to take some precautions, because a person who carries the gene change could in theory have prions in their body before any symptoms. The risk to others is thought to be very low: no one is known to have caught prion disease from a healthy carrier. The UK guidance applies to relatives who have been told by a specialist that they are at risk.
- Do not give blood, and do not donate organs or tissues, including bone marrow, sperm, eggs or breast milk.
- Before any medical, surgical or dental procedure, tell whoever is treating you, so that they can decide whether special arrangements are needed for the instruments. Extra precautions are needed only for a few kinds of operation (on the brain, spinal cord, nerves inside the skull, pituitary gland, back of the eye, or deep inside the nose); routine dentistry and gut endoscopy use normal procedures.
- You are advised to tell a family member or someone close to you about your risk, and your GP should include it in referral letters for surgery.
- A relative who has a gene test and does not carry the family’s gene change is not at increased risk under the public health guidance, though the blood service has its own rules (see below).
The review led from the National Prion Clinic stresses that these steps should not cause needless worry about living together or close relationships, and that urgent medical care should never be delayed because of them. The National Prion Clinic or a genetic counsellor can say which rules apply to a particular family.
More detail who counts as at risk, and where the UK documents differ
The 2026 review states that the UK, USA and many EU countries ask relatives of patients with inherited prion disease to defer from blood donation and organ transplantation, and that in the UK at least they should inform surgeons before invasive procedures; the risk “must be very low, as there are no documented iatrogenic transmissions from healthy mutation carriers, but [is] hard to quantify with certainty”. The three UK documents behind this do not define the at-risk group in quite the same way:
- UKHSA public health action guidance (version 1.6, October 2015; the 2025 page update was a rebranding only). At increased risk: people tested and found to carry a disease-causing PRNP mutation, and untested blood relatives of a patient or carrier who know about their relative’s status and their own risk (“up to 50%” of whom will develop the disease). Relatives tested and found not to carry the mutation “are not at increased risk of CJD”. Public health precautions cannot be applied to relatives who have not been told of their risk.
- ACDP Annex J, presurgical assessment (revised August 2017, England). Every surgical and endoscopy patient should be asked whether they have been notified that they are at increased risk for public health purposes. A family-history risk is flagged by any of: genetic testing showing significant risk; a blood relative known to carry a disease-causing mutation; or two or more blood relatives affected by prion disease. Special instrument precautions then apply only to high-risk tissues (brain, spinal cord, posterior eye, and surgery breaching the olfactory epithelium); all other surgery, including gastrointestinal endoscopy, proceeds normally. Annex J does not say how a relative’s own negative test affects these questions.
- ACDP Part 4, infection prevention and control (revised February 2015), the part Annex J refers to for the precautions themselves. It defines the family-history group in the same three ways as Annex J. For these patients, instruments used on high-infectivity tissue (brain, spinal cord, the optic nerve and the intracranial parts of other cranial nerves, cranial ganglia, posterior eye, pituitary) or medium-infectivity tissue (spinal ganglia, olfactory epithelium) must be single-use, destroyed, or quarantined for re-use only on the same patient; other tissue needs no special precautions. Routine dental treatment should not be refused, and dental instruments are handled as in any other low-risk surgery. Most routine clinical contact needs no extra precautions, and GPs are asked to record the risk status in the patient’s notes. Part 4 does not address relatives who test negative, and its endoscopy advice sits in a separate annex (Annex F) that we did not read.
- UK blood services donor selection guidelines (JPAC, “Prion-associated diseases” entry, February 2022). Must not donate if at familial risk: two or more blood relatives with prion disease, or informed after genetic counselling that they are at risk. Someone with two or more affected relatives who is told after genetic counselling that they are not at risk may be accepted at the discretion of a designated clinical support officer. Genetic testing is not mentioned as such.
So the guidance agrees on the precautions but differs on thresholds: UKHSA treats a known mutation in one relative as enough and a negative test as clearing a relative, while the blood service’s rule turns on two or more affected relatives or a genetic counsellor’s advice, with discretion for those told they are not at risk.
Sources: Mead et al., Lancet Neurol 2026 (full text read; “Public health implications”). UKHSA: CJD, public health action following report of new case or person at increased risk (guidance version 1.6, October 2015; page updated 15 July 2025). ACDP TSE subgroup: Minimise transmission risk of CJD and vCJD in healthcare settings, Annex J (August 2017). ACDP TSE guidance Part 4: infection prevention and control of CJD and vCJD in healthcare and community settings (February 2015; Tables 4a and 4c, paragraphs 4.19–4.21 and 4.70–4.72). JPAC donor selection guidelines: prion-associated diseases (February 2022). All checked 2 November 2026.